LAMEA Clot Management Devices Market By Product Type (Percutaneous Thrombectomy Devices, Embolectomy Balloon Catheters, Catheter-Directed Thrombolysis devices, Neurovascular Embolectomy Devices), End User (Hospitals, Diagnostic Centers)
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the LAMEA Clot Management Devices Market
Market Report Description
Blood Clotting also known as coagulation is the bodys response to an injury to prevent bleeding. However, a clot can be harmful when it forms abnormal flows through the vessels. The excessive formation of clots in the blood leads to different diseases such as brain stroke, heart attack and severe leg pain. Rising incidences of Heart failure, Brain disorder and other clot related problems have initiated the organizations to take measures against the problem. Clot management devices are one of the major treatments available in the market. Governments and healthcare organization have increased their investments for developing and enhancing the healthcare infrastructure. Such as The Healthcare Information Technology for Economic and Clinical Health Act is investing $20 billion in health information technology infrastructure. That is helping patients to avail the advanced medical facilities; hence it would affect the growth of the market. Asia-Pacific with increasing per capita income and high economic potentials would emerge as a prominent market during the forecast period.
Based on the product type, the Clot Management Devices market is segmented into Percutaneous Thrombectomy Devices, Embolectomy Balloon Catheters, Catheter-Directed Thrombolysis (CDT) devices, Neurovascular Embolectomy Devices and Inferior vena cava filters. Based on End user Type, the market is segmented into Hospitals and Diagnostic Centres. Based on Country, LAMEA Clot Management Devices market is segmented into Brazil, ARGENTINA, UAE, Saudi Arabia, South Africa, Nigeria and Rest of LAMEA. Brazil remained the dominant Country in the LAMEA Clot Management Devices market in 2015. UAE and Saudi Arabia would witness promising CAGR during the forecast period (2016-2022).
The report covers the analysis of key stake holders of the Clot Management Devices market. Key companies profiled in the report include Teleflex Inc., Edwards Lifesciences Corporation, Medtronic Plc, Boston Scientific Corporation, Lemaitre Vascular, Inc., Straub Medical AG, Cook Medical Inc. and Johnson & Johnson.